Skip to main content

RVPH

Stock
Health Care
Biotechnology

Performance overview

RVPH Price
Price Chart

Forward-looking statistics

Beta
0.44
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

reviva pharmaceuticals is a pharmaceuticals company located in 5941 optical ct, san jose, california, united states.

Company info

SectorHealth Care
IndustryBiotechnology
Employees14
Market cap$42.9M

Fundamentals

Enterprise value$12.7M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity-0.05

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.78
Dividend per share
Revenue per share
Avg trading volume (30 day)$783K
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth+3.2
Credit-5.6
Liquidity+0.4
Inflation+4.4
Commodities+1.2
Interest Rates+1.6

Valuation

Dividend yield0.00%
PEG Ratio-0.44
Price to sales
P/E Ratio-0.44
Enterprise Value to Revenue
Price to book-4.01

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day
Ex. dividend day

News

FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial

The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.

Benzinga (January 10, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free